Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for patients with sensitizing EGFR mutation-positive non-small cell lung cancer (NSCLC) [1]. Pivotal studies on first-generation EGFR TKIsgefitinib and erlotinib have confirmed improvement in progression-free survival (PFS) and objective response rate (ORR) but failed to demonstrate a statistically significant overall survival (OS) benefit over chemotherapy in patients with EGFR mutation-positive advanced NSCLC [2 –9].

Source: Lung Cancer - February 23, 2021 Category: Cancer & Oncology Authors: Ying Cheng, Tony S. Mok, Xiangdong Zhou, Shun Lu, Qing Zhou, Jianying Zhou, Yingying Du, Ping Yu, Xiaoqing Liu, Chengping Hu, You Lu, Yiping Zhang, Ki Hyeong Lee, Kazuhiko Nakagawa, Rolf Linke, Chew Hooi Wong, Yiyun Tang, Fanfan Zhu, Keith D. Wilner, Yi-L Source Type: research